Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 15Prostatic Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Prostatic Intraepithelial Neoplasia 2Fractures, Bone 2Desmoid Tumors 2Triple Negative Breast Neoplasms 1Recurrence 1Precancerous Conditions 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Carcinoma, Ovarian Epithelial 1Breast Carcinoma In Situ 1Breast Cancer Patients in Premenopausal 1Breast Cancer Organoids 1Bone Diseases, Metabolic 1

Interventions

Toremifene 1Tamoxifen 1Ovariectomy 1Gonadotropin-Releasing Hormone 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-receptor-positive Breast Cancer × Toremifene × Clear all
NCT05801705 2023-05-18

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Unknown
700 enrolled
Breast

Hormone-receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡